Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT03666728
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Safety, Tolerability and PK/PD of SHR1459 in Healthy Volunteers
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03668509
- Locations
- 🇨🇳
Xu qian, M.D. Ph.D, Shanghai, China
Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT03664297
- Locations
- 🇨🇳
Blood disease hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT03645876
- Locations
- 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China
The PK/PD Study of SHR0532 Tablets in Healthy Subjects
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03645278
The PK/PD Study of A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT03634436
- Locations
- 🇨🇳
FuWai Hospital , Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 396
- Registration Number
- NCT03605706
- Locations
- 🇨🇳
81 Hospital Nanjing, Nanjing, Jiangsu, China
A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT03603132
- Locations
- 🇨🇳
The third xiangya hospital Hospital,of central south university, Changsha, Hunan, China
A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 272
- Registration Number
- NCT03603951
- Locations
- 🇨🇳
Beijing Cancer Hospital, Peking University, Beijing, Beijing, China
SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 4
- Registration Number
- NCT03596658
- Locations
- 🇨🇳
The 307th Hospital of Military Chinese People's Liberation Army, Beijing, Beijing, China
© Copyright 2024. All Rights Reserved by MedPath